Skip to main navigation
logo
  • Overview
  • Shareholder Information
    • Stock Quote & Chart
    • Financial Filings
    • Shareholder Structure
    • Shareholder Structure (NL)
    • Prospectus
    • Prospectus (NL)
    • Shareholder Meetings
    • Analyst Coverage
    • Transparency Notifications
    • Conversion Table
    • Conversion Table (NL)
  • Events & Presentations
  • News
  • Corporate Governance
    • Governance Overview
    • Governance Overview (NL)
    • Board of Directors
    • Management
  • IR Contact
    • Email Alerts
    • Contact IR

News

News

September 29, 2023
Oxurion Publishes First Half 2023 Results
EN
NL
September 18, 2023
Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program
PDF Version
August 11, 2023
Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program
PDF Version
July 25, 2023
Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB  
PDF Version
June 15, 2023
Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC
PDF Version
June 12, 2023
Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
PDF Version
June 1, 2023
Oxurion to Participate in Upcoming Conferences
PDF Version
May 25, 2023
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
PDF Version
May 22, 2023
Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC
PDF Version
May 15, 2023
Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 18

Section Title

  • Who We Are
  • THR-149
  • News & Events
  • Let’s Talk

Connect with Us

  • LinkedIn
  • Twitter
  • Ⓒ2023 Oxurion NV. All rights reserved.